81 Result: FDA
FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026
Agency also grants two petitions to expand alternative food color options Silver Spring, MD / CRWE PRESS RELEASE / February 05, 2026 - Today, the U.S. Food and Drug Administration took additional steps to support the transition of our nation&. Read more
FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026
Silver Spring, MD / CRWE PRESS RELEASE / January 12, 2026 - The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes disease in pediatric patients. “With today&rs. Read more
FDA Approves Two Oral Therapies to Treat Gonorrhea
December 13th, 2025
Approvals Are for Uncomplicated Urogenital Gonorrhea Silver Spring, MD / CRWE PRESS RELEASE / December 12, 2025 - The U.S. Food and Drug Administration recently approved two new oral medicines to treat a common sexually transmitted infection calle. Read more
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025
Silver Spring, MD / CRWE PRESS RELEASE / December 3, 2025 - The U.S. Food and Drug Administration today granted approval for Avance (acellular nerve allograft-arwx) in surgical implantation. Avance is a peripheral nerve scaffold approved for sensory . Read more
Bondezz™ Appoints Brian Colando as Vice President of Sales to Lead Wholesale Expansion
October 24th, 2025
Las Vegas, NV / CRWE PRESS RELEASE / October 24, 2025 — FOR IMMEDIATE RELEASE — Bondezz™, today announced the appointment of Brian Colando as Vice President of Sales. In this role, Brian Colando will oversee the development of. Read more
Sage Therapeutics' SAGE-718 Gets FDA ODD; Bullish View On TeraWulf
October 18th, 2023
Shares of Sage Therapeutics, Inc. (Nasdaq: SAGE), a leading biopharmaceutical company specializing in neurological and neuropsychiatric disorders, surged over 5% in pre-market trading after the company said that the U.S. Food and Drug Administration . Read more
Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
October 02nd, 2023
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more
Breaking: FDA Greenlights Profound Medical's TULSA AI Module
September 26th, 2023
Shares of Profound Medical Corp. (Nasdaq: PROF) surged by more than 10% in after-hours trading after it announced FDA clearance for its Thermal Boost module in conjunction with TULSA-PRO, which allows surgeons to treat various prostate conditions, in. Read more
FDA Clearance Sparks Femasys Surge; THOR Industries Tops Estimates
September 25th, 2023
Shares of Femasys Inc. (Nasdaq: FEMY) surged by over 100% in after-hours trading following the company's announcement of receiving 510(k) Clearance from the United States Food and Drug Administration (FDA) for its groundbreaking infertility treatment. Read more
Pre-market Shock: ARS Pharmaceuticals Faces Setback
September 20th, 2023
Shares of ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) plunged over 40% following the announcement that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for neffy (epinephrine na. Read more
PDUFA Extension Fuels Iovance Biotherapeutics; PTC Therapeutics Faces Setback
September 15th, 2023
Shares of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) surged over 10% after the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) for lifileucel due to resource constraints. The new target action date is . Read more
Semtech Posts Upbeat Results, Outlook Falls Short; FDA Panel Backs Alnylam's Patisiran
September 13th, 2023
Semtech Corporation (Nasdaq: SMTC), a technology company specializing in semiconductor solutions, reported earnings of $0.11 per share for the second quarter of fiscal 2024, surpassing the consensus EPS estimate of $0.02. Quarterly sales for Semtech . Read more
Spirit Airlines Lowers Outlook; Alnylam Stock Halted Amid FDA Panel Review
September 13th, 2023
Shares of Spirit Airlines, Inc. (NYSE: SAVE) experienced a dip in pre-market trading as it revised downwardly its third-quarter 2023 outlook. The company now anticipates revenues between $1.245 billion and $1.255 billion, a notable decrease from its . Read more
Breaking: Asset Sale Deal Ignites Avalo Therapeutics
September 12th, 2023
Shares of Avalo Therapeutics, Inc. (Nasdaq: AVTX) surged by more than 40% following the company's announcement of a purchase agreement with AUG Therapeutics, LLC (AUG), wherein it will sell its rights, assets, and interests related to the 800 Series . Read more
Biopharmaceutical Giant Amgen to Settle FTC and State Challenges to its Horizon Therapeutics Acquisition
September 01st, 2023
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products Washington D.C. / CRWE PRESS RELEASE / September 1, 2023 - The Federal Tra. Read more
Want To Find Some News?
News By Industries
Recent Post
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026




Member Login